Researchers from Philadelphia, USA, examined trends in hospitalization and mortality rates from GI toxicity during the 1990s.
The team performed an analysis of secular trends of hospitalization and mortality rates from peptic ulcer disease, upper GI bleeding, and any GI bleeding using data from the National Hospital Discharge Survey.
Their aim was to determine the impact of the of proton pump inhibitors, over-the-counter preparations of nonsteroidal anti-inflammatory drugs (NSAIDs), and histamine type 2 receptor antagonists on these rates.
GI data were compared to those for sales of NSAIDs, aspirin, and acid suppression medications from 1992 to 1999.
|Acid suppression medication sales show no correlation with peptic ulcer disease rates.|
|American Journal of Gastroenterology|
The team discovered that, from 1992 to 1999, annual rates of hospitalization and mortality per 100,000 population, for peptic ulcer disease declined from 205 to 165 and 8 to 6, respectively.
They found calendar year to be negatively correlated with both peptic ulcer disease hospitalization rates and mortality rates.
The correlations were not significant for upper or any GI bleeding.
The researchers found sales of acid suppression medications to be negatively correlated with peptic ulcer disease hospitalization rates and mortality rates.
There was no correlation between sales of NSAIDs and hospitalization or mortality rates from peptic ulcer disease or GI bleeding.
In their conclusion, Dr James Lewis's team state, "Despite changing patterns of use of NSAIDs and acid suppression medications during the 1990s, mortality rates from GI bleeding and peptic ulcer disease have been relatively stable, with an apparent decline in hospitalization rates and mortality from peptic ulcer disease".
"Changing rates of peptic ulcer disease morbidity and mortality were temporally related to increasing sales of antiulcerants, but not to change in sales of NSAIDs".